Press releases

Ferring strengthens growth hormone franchise Zomacton® through acquisition of ZomaJet™ needle-free injector device

  •  Ferring enters agreement with Antares Pharma Inc. for worldwide rights to ZomaJet™ needle-free injector device
  • ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), indicated to treat Growth Hormone Deficiency in children and Turner Syndrome in girls
  • ZomaJet helps increase adherence to treatment through its needle-free feature and the ability to self-administer 1,2,3

Saint-Prex, Switzerland – 10 October 2017 Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto injector device.

This transaction is subject to customary closing conditions. Antares will continue to manufacture and supply the ZomaJet device until completion of existing supply arrangements, expected by the end of 2018.

ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), a treatment indicated for the treatment of Growth Hormone Deficiency (GHD) in children and Turner Syndrome in girls.  

“Through the acquisition of ZomaJet, we are consolidating our Zomacton franchise and commitment to improving quality of life and care for children with growth disorders,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “ZomaJet addresses the common problem of needle fear in children, lowering the burden for patients and care givers and leading to better adherence to treatment.”

Ferring is a recognised speciality player in endocrinology, with a commitment to addressing the unmet medical needs of patients with childhood growth disorders including GHD and Turner Syndrome.

- Ends -

About ZomaJet™

ZomaJet devices are needle-free delivery systems for the administration of Zomacton® (somatropin) human growth hormone (hGH).

 About Zomacton®

Zomacton® (somatropin) is a synthetic human growth hormone (hGH) produced by recombinant DNA technology. The main use for the product is to treat Growth Hormone Deficiency (GHD) in children and Turner Syndrome in girls.

About Ferring Pharmaceuticals:

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit www.ferring.com.

Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews

Ferring Corporate Communications Team:

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

 Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

References

Haverkamp F. & Gasteyger G. Journal of Medical Economics 2011; 14(4): 448-457

2 Wickramasuriya B.P. et al, Horm Res 2006; 65(1): 18-22

3 Main K.M. et al, Acta Paediatr 1995; 84(3): 331-334

 

See more Press releases

Headquarters

FERRING INTERNATIONAL CENTER S.A.
CH. DE LA VERGOGNAUSAZ 50
1162 SAINT-PREX
SWITZERLAND

TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10

CONTACT

Global Locator